U.S. Department of Health and Human Services
 

 Contact Info

 
Tel: +1 301 435 5055
Email: howarda@intra.niddk.nih.gov
 

 Training and Experience

 
M.D., College of Physicians and Surgeons, Columbia University, 1973

Staff Clinician, Kidney Disease Section, NIDDK, NIH, 2002–Present

Medical Officer, Kidney Disease Section, NIDDK, NIH, 1991–2002

Expert Consultant in Nephrology, NIH Georgetown University Hospital, 1980–1991

Nephrology Fellow, Georgetown University Hospital, 1978–1980

Junior and Senior Assistant Medical Resident, Georgetown University Hospital, 1975–1978

Surgical Intern and Junior Assistant Resident, Columbia Presbyterian Hospital and Georgetown University Hospital, 1973–1975
 

 Related Links

 

    Howard A. Austin III, M.D.

    Staff Clinician, Kidney Diseases BranchKidney Diseases Section
    Specialties: Clinical Research

    Research Summary

    Research Goal

    The ultimate goal is to better understand the pathogenesis of these immune mediated kidney diseases so that immunosuppressive therapy can be targeted and thereby optimize efficacy and minimize toxicity.

    Current Research

    We study the natural history, pathogenesis, prognosis, and treatment of immune mediated kidney diseases.  Our studies have focused on the efficacy and toxicity of immunosuppressive treatment regimens for proliferative lupus nephritis, membranous lupus nephropathy, and idiopathic membranous nephropathy.  We have completed prospective randomized clinical trials of immunosuppressive drug therapies for proliferative lupus nephritis and membranous lupus nephropathy.  A prospective clinical study of combination rituximab and cyclosporine therapy for idiopathic membranous nephropathy is in progress. ​

    Applying our Research

    Patients with immune mediated kidney diseases are at increased risk for life-threatening (and life-altering) complications, including chronic kidney failure, cardiovascular and cerebrovascular disease, as well as thromboembolic events. While non-immunosuppressive therapies are available that reduce the risk of these complications to some degree, it is widely recognized that patients benefit most when they achieve a remission of the kidney disease, either spontaneously or from treatments that suppress their abnormally active immune system.

    Need for Further Study

    To optimize the treatment of immune mediated kidney diseases, additional studies are needed to further define the pathogenesis of these conditions and to develop novel treatment strategies that target the underlying immunologic abnormalities.